Skip to results
Modify your search
NARROW
1-20 of 85
Authors: Caterina Giannini
Journal Article
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics
Neuro-Oncology Advances, Volume 7, Issue 1, January-December 2025, vdae228, https://doi.org/10.1093/noajnl/vdae228
Published: 03 January 2025
Journal Article
INNV-27. TEMOZOLOMIDE FOR PATIENTS WITH AGGRESSIVE PITUITARY TUMORS: A CASE SERIES
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii174, https://doi.org/10.1093/neuonc/noae165.0689
Published: 11 November 2024
Journal Article
BIOM-71. EXPANDING THE SPECTRUM OFTERT PROMOTER NON-CANONICAL SEQUENCE VARIANTS IN CNS TUMORS: A CASE SERIES
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii36, https://doi.org/10.1093/neuonc/noae165.0143
Published: 11 November 2024
Journal Article
EPCO-31. THE GERMLINE POLYMORPHISM RS55705857 IS ASSOCIATED WITH A POOR SURVIVAL IN ASTROCYTOMA, IDH-MUTANT, GRADE 2
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii8, https://doi.org/10.1093/neuonc/noae165.0030
Published: 11 November 2024
Journal Article
EXTH-81. A RARE CASE OF RELENTLESSLY PROGRESSIVE METASTATIC PINEOCYTOMA MANAGED WITH SEQUENTIAL MULTIMODAL THERAPY
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii255, https://doi.org/10.1093/neuonc/noae165.1011
Published: 11 November 2024
Journal Article
LTBK-07. PROGRESSION-FREE AND OVERALL SURVIVAL RESULTS OF ECOG-ACRIN E3F05: A PHASE 3 INTERGROUP TRIAL OF RADIATION ± TEMOZOLOMIDE FOR GRADE II GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii1–viii2, https://doi.org/10.1093/neuonc/noae165.1303
Published: 11 November 2024
Journal Article
BIOM-44.18F-DOPA-PET THRESHOLDS FOR BOTH NEWLY DIAGNOSED AND RECURRENT ASTROCYTOMA USING PATHOLOGICAL GROUPING OF SPATIALLY CORRELATED BIOPSIES
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii29, https://doi.org/10.1093/neuonc/noae165.0117
Published: 11 November 2024
Journal Article
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 319–330, https://doi.org/10.1093/neuonc/noae170
Published: 30 August 2024
Journal Article
PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v172, https://doi.org/10.1093/neuonc/noad179.0653
Published: 10 November 2023
Journal Article
PATH-33. MORPHOLOGY, MOLECULAR FEATURES, AND CLINICAL BEHAVIOR OF METHYLATION CLASS PLEOMORPHIC XANTHOASTROCYTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v175, https://doi.org/10.1093/neuonc/noad179.0663
Published: 10 November 2023
Journal Article
CTNI-03. EFFICACY OF WSD0922-FU IN OSIMERTINIB-RESISTANT NSCLC WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES – UPDATES FROM THE DOSE ESCALATION COHORT OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v73, https://doi.org/10.1093/neuonc/noad179.0285
Published: 10 November 2023
Journal Article
TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS
Neuro-Oncology Advances, Volume 5, Issue Supplement_3, August 2023, Page iii36, https://doi.org/10.1093/noajnl/vdad070.140
Published: 04 August 2023
Journal Article
Genomic markers of recurrence risk in atypical meningioma following gross total resection
Neuro-Oncology Advances, Volume 5, Issue 1, January-December 2023, vdad004, https://doi.org/10.1093/noajnl/vdad004
Published: 10 January 2023
Journal Article
PATH-36. GENOMIC MARKERS OF RECURRENCE RISK IN ATYPICAL MENINGIOMA FOLLOWING GROSS TOTAL RESECTION
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii158, https://doi.org/10.1093/neuonc/noac209.609
Published: 14 November 2022
Journal Article
PATH-34. SOLITARY FIBROUS TUMOR: NATURAL HISTORY AND PROGNOSIS IN ACCORDANCE WITH THE WHO 2021 CLASSIFICATION OF CNS TUMORS
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii157–vii158, https://doi.org/10.1093/neuonc/noac209.607
Published: 14 November 2022
Journal Article
EPCO-38. TYPE B ULTRA LONG-RANGE INTERACTIONS IN PFAS (TULIPS) ARE RECURRENT EPIGENOMIC FEATURES OF PFA EPENDYMOMA
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii124, https://doi.org/10.1093/neuonc/noac209.472
Published: 14 November 2022
Journal Article
PATH-12. DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT: A COMPREHENSIVE SEQUENCING AND HIGH-RESOLUTION GENOME-WIDE COPY NUMBER ANALYSIS
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii152, https://doi.org/10.1093/neuonc/noac209.585
Published: 14 November 2022
Journal Article
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 28–36, https://doi.org/10.1093/neuonc/noac205
Published: 17 August 2022
Journal Article
EPCT-04. Stereotactic biopsy split-course radiation therapy for diffuse midline glioma of the pons (SPORT-DMG): Early phase II enrolling clinical trial
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i36, https://doi.org/10.1093/neuonc/noac079.132
Published: 03 June 2022
Journal Article
ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i4, https://doi.org/10.1093/neuonc/noac079.007
Published: 03 June 2022
